VTGN News and Press, VistaGen Therapeutics Inc. From 03/09/23

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced key updates regarding its phase 1 clin...

U.S. Phase 1 study with newly optimized formulation intended to facilitate Phase 2B development of itruvone as a stand-alone treatment of major depressive disorder Top line results anticipated in Q2 2023 Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company...

VistaGen ( NASDAQ: VTGN ) down 4.3% premarket after filing a prospectus to sell 12.4M common shares by selling stockholders. The company will not receive any proceeds from the sale of the shares offered. This prospectus does not necessarily mean that the selling stockholders w...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the 43rd annual Cowen Health C...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and ho...

The USPTO has granted a patent for Vistagen's ( NASDAQ: VTGN ) PH80 nasal spray for treatment of migraine. VTGN shares up 6.8% premarket. The newly issued patent will be in effect until at least 2040. PH80 is an investigational pherine nasal spray designed with a potential...

PH80 patent portfolio now includes U.S. patents for treatment of both hot flashes and migraine Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous ...

VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Conference Call February 07, 2023 05:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Chief Financial Officer Conference Ca...

Shares of clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN ) lost ~20% Wednesday after the company said that it has yet to decide on resuming a Phase 2 trial for its anxiety disorder candidate PH94B. Recently, the company has proposed adjustments to the Phase 2 trial PA...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on its fiscal year 2023 third quarter e...